Aflibercept is a biopharmaceutical drug inhibiting of vascular endothelial growth factor (VEGF) signaling and composed of the extracellular domains of human VEGF receptors 1 and 2 that are fused to the Fc portion of the human IgG1 immunoglobulin. It is important to determine an appropriate dose for medical optimization, but little amount of intraocular fluid is able to collect as a specimen in the treatment of retina. To offer the quantitative assessment method of aflibercept in biological matrix, the primary structure was confirmed using a quadrupole time-of-flight (Q-TOF) mass spectrometer LCMS-9030, and quantitative analysis was performed with a triple quadrupole mass spectrometer LCMS-8060 by using nSMOL (nano-surface and molecular orientation limited proteolysis) technology.
- Content Type:
- Document Number:
- ASMS 2020 - WP 487
- Product Type:
- Liquid Chromatography Mass Spectrometry
- Pharma & Biopharma, LCMS-9030 Q-TOF Mass Spectrometer
- File Name:
- File Size:
Question about this literature?